NewBiologix

NewBiologix SA is a technology innovation company developing a proprietary and breakthrough DNA integration platform for the advanced engineering of human and mammalian cell lines. NewBiologix is committed to improve the generation and production of viral vectors used in gene and cell therapies by combining innovative and proprietary bioinformatics platform with advanced R&D experimentation. Next-generation sequencing (NGS)-based genome characterization will be used to develop an innovative and proprietary bioinformatics platform that will help cell line engineering through a combination of exceptionally in-depth datasets, sophisticated genomic analyses, and advanced R&D experimentation. NewBiologix’ technologies will be applied to human (HEK-293) and mammalian (CHO) cell lines engineered to be readily adaptable to meet the viral vector demands and requirements over a full range of products. With a strong Series A financing and an experienced start-up team established, NewBiologix anticipates cell line prototypes will be ready for beta testing with key collaborators by 2024 with the goal of commercially available viral production cell line lines by 2025.